Osteoporosis Drugs Market to Reach US$ 18 Bn at CAGR of 3.8% from 2021 to 2031

The Osteoporosis Drugs Market is likely to grow voraciously, i.e. at a CAGR of 2.6% between 2022-2031, reaching US$ 18 Bn. Augmented and virtual reality are abreast with advanced technologies on a significant count. VR and AR do have loads of potential for offering in the healthcare vertical. The application areas include surgery and training simulation, and patients care and treatment.

The global osteoporosis drugs market is valued at US$ 12.5 Bn at present, and is expected to progress at a modest CAGR of 3.8% from 2021 to 2031, to account for US$ 18 Bn by 2031.

Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/2983

The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market.

However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits the growth of the market.

Company Profiles:

Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Merck & Co, Inc.
Novartis AG
Amgen, Inc.
Novo Nordisk A / S
Actavis plc
Pfizer, Inc.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd
Other

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/2983

In North America, the prevalence of osteoporosis is high primarily due to increasing geriatric population, growing obesity, and rising prevalence of lifestyle associated diseases in the region.

According to the U.S. Department of Health and Human Services, in the U.S., approximately 250,000 hip fractures are associated with osteoporosis.

In Europe, increasing aging population, changing lifestyles, and increasing consumer awareness about osteoporosis care are driving the growth of the osteoporosis drug market.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/2983

According to International Osteoporosis Foundation, approximately 27.5 million people in Europe suffered from osteoporosis in 2010, and the number is expected to reach 33.9 Mn by 2030.

However, the growth of osteoporosis market in Asia Pacific is much due to rising geriatric population and changing lifestyles in the region. Osteoporotic patients have a higher risk of hip fractures, owing to a major cause of morbidity and mortality.

According to the International Osteoporosis Foundation, by 2050, approximately 1/2 of the world's osteoporosis hip fractures would occur in women in Asia.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/osteoporosis-drugs-market.asp

Market Segmentation

By Drug Type

Bisphosphonates
Parathyroid Hormone Therapy Drugs
Calcitonin
Selective Estrogen Receptors Modulators (SERMs)
RANK Ligand Inhibitors

Related Reports:

Meningococcal Vaccines Market - https://www.persistencemarketresearch.com/market-research/meningococcal-vaccines-market.asp

Autogenous Vaccine For Aquaculture Market - https://www.persistencemarketresearch.com/market-research/autogenous-vaccine-for-aquaculture-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.